Hydrinity Accelerated Skin Science, a fast-growing professional skincare brand based in the US, will expand into Singapore and Hong Kong via a new partnership with Philomedicare Alliance Pte Ltd., a clinical-focused medical technology provider located in Singapore and Hong Kong.
“We are thrilled to partner with Philomedicare Alliance Pte Ltd.,” said Brent Nixon, chief operating officer of Hydrinity. “Philomedicare Alliance Pte Ltd. is led by a team of world-class trained physicians and known for its emphasis on the most clinically proven products. Their commitment to the highest level of training and support will give us a distinct market advantage as we introduce Hydrinity to these important lucrative markets.”
Led by a group of physicians from Europe and Asia, Philomedicare Alliance Pte Ltd. has become trusted partners for medical professionals in the region.
“Our enterprise is committed to only delivering the best quality products that are backed by rigorous clinical evidence, this is why we believe in Hydrinity,” said Oliver Chen, CEO of Philomedicare Alliance Pte Ltd. “After thorough testing and evaluation of Hydrinity over the past six months, its apparent Hydrinity stands apart from other skincare brands.”
He continued, “Hydrinity is unmatched in its ability to generate rapid clinical results and positive patient responses.”
Both Singapore and Hong Kong, recognized as two of the “East Asian Tigers,” are renowned for their continued economic growth and thriving aesthetics markets since the 1960s. With a combined skincare market opportunity exceeding $1 billion, these regions are known for a high demand for advanced skincare products and services, particularly those focused on medical aesthetic procedures such as Botox, fillers and laser treatments.
Hong Kong, with its proximity to mainland China, has a larger and more established market, while Singapore is recognized for its premium clinics that emphasize natural-looking results.
